Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' cholesterol drug pelacarsen, developed with Ionis, failed to improve cardiovascular outcomes in a late-stage trial, despite reducing harmful cholesterol. Novartis stock fell 3%. Amgen and Eli Lilly, developing rival treatments, also saw stock declines. Analysts note the setback raises risks for the multibillion-dollar Lp(a) treatment market. Novartis faces patent expirations, and the trial's impact extends beyond the company.
How this was made
The 30-second read
Why it matters
The failure challenges the Lp(a) hypothesis and pressures peers developing similar agents, potentially reshaping investment theses in cardiovascular biotech.
Market read
The trial miss is a material event for the cardiovascular biotech sector, prompting immediate price moves in the involved companies.
What to watch
Novartis' broader portfolio and upcoming data from other indications could offset the negative impact of this single trial.
Background
Novartis' pelacarsen trial was a late‑stage study targeting Lp(a), a genetically driven cholesterol risk factor with no approved therapies.
Ticker impact
Novartis reported its pelacarsen trial failed to improve cardiovascular outcomes, causing its stock to fall 3% on Monday.
Potential further downside of 3-5% as investors reassess pipeline value.
First disclosure of trial failure with immediate stock reaction; market impact evident.
Amgen shares fell about 5% in extended trading after Novartis' trial setback raised concerns for its own Lp(a) drug olpasiran.
Short-term downside of 4-6% as investors weigh read‑through risk.
Peer trial failure creates sector‑wide risk perception.
Eli Lilly's Lp(a) candidate lepodisiran saw limited impact from Novartis' failure, but the stock was mentioned as a peer.
Minor short‑term movement, likely within ±2%.
No direct trial data for Lilly; effect is indirect.
Market effects
The Lp(a) therapeutic space faces heightened risk, potentially dampening biotech valuations in cardiovascular drug development.
European biotech firms with similar pipelines may see pressure, though impact is limited to US‑listed peers.
Global investors tracking cardiovascular innovation may reassess exposure across the sector.
Counterpoint
If deeper Lp(a) reductions can still demonstrate clinical benefit, the setback may be a temporary price overreaction.
Key entities
- CompanyNovartis
Swiss pharma giant leading the pelacarsen trial.
- CompanyAmgen
US biotech developing olpasiran, another Lp(a) drug.
- CompanyEli Lilly
US pharma with lepodisiran, an Lp(a) candidate.
- CompanyIonis Pharmaceuticals
Co‑developer of pelacarsen.
